New combo therapy shows promise for aggressive lung cancer in japanese patients
NCT ID NCT06812260
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (HLX10) that helps the immune system fight cancer, combined with standard chemotherapy, in 26 Japanese patients with extensive-stage small cell lung cancer that has not been treated before. The goal is to see if the combination shrinks tumors and improves survival. Researchers will also monitor side effects and how the drug moves through the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kansai Medical University Hospital Department of Respiratory Oncology
Hirakata, Osaka, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug combo outperform standard chemo for tough lung cancer?
- New drug cocktail aims to shrink tough lung cancers
- New drug cocktail aims at resistant lung cancer
- New drug combo aims to outperform standard care in aggressive lung cancer
- New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
- New combo therapy targets tough lung cancer in early trial